1. Scrip
  3. >>Anti-infective

Moderna Takes The Lead With Plan To Tackle New COVID-19 Variants

New Tweaked Booster To Enter Phase I Study

 
• By Andrew McConaghie

Moderna has unveiled plans to develop a new booster vaccine, tweaked to meet the threat posed by the South African strain.

Moderna aims to produce up to 1 billion doses of its existing vaccine in 2021 - but a new booster to target variants will also enter Phase I trials.

Moderna, one of the companies behind the ground-breaking mRNA vaccines against COVID-19, has produced proof that its product still works against new variants of the virus, but has plans in place to meet the threat of other variants.

Its data follow hot on the heels of a similar study from fellow mRNA vaccine developer BioNTech, suggesting that the first-to-market pioneers are also likely

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapy Areas

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 
• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.